S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

(BIO.B) Stock Forecast, Price & News

0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $605.65
50-Day Range
MA: $566.92
52-Week Range
Now: $605.65
Volume25 shs
Average Volume107 shs
Market Capitalization$18.07 billion
P/E Ratio5.18
Dividend YieldN/A
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.


Overall MarketRank

0.67 out of 5 stars

Medical Sector

1069th out of 1,558 stocks

Analytical Instruments Industry

22nd out of 25 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNYSE:BIO.B



Sales & Book Value

Annual Sales$2.31 billion
Cash Flow$7.12 per share
Book Value$192.32 per share


Net Income$1.76 billion


Market Cap$18.07 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO.B News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

(BIO.B) (NYSE:BIO.B) Frequently Asked Questions

How has (BIO.B)'s stock price been impacted by COVID-19 (Coronavirus)?

(BIO.B)'s stock was trading at $350.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIO.B stock has increased by 73.0% and is now trading at $605.65.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than (BIO.B)?

Wall Street analysts have given (BIO.B) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (BIO.B) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is (BIO.B)'s next earnings date?

(BIO.B) is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for (BIO.B)

How were (BIO.B)'s earnings last quarter?

(BIO.B) (NYSE:BIO.B) posted its earnings results on Thursday, October, 29th. The company reported $3.00 EPS for the quarter. The firm earned $647.26 million during the quarter. (BIO.B) had a return on equity of 3.77% and a net margin of 147.91%.
View (BIO.B)'s earnings history

Who are some of (BIO.B)'s key competitors?

Who are (BIO.B)'s key executives?

(BIO.B)'s management team includes the following people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 70, Pay $2.12M)
  • Mr. Ilan Daskal, Exec. VP & CFO (Age 54, Pay $754.23k)
  • Dr. Andrew J. Last, Exec. VP & COO (Age 60, Pay $825.67k)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 58, Pay $663.07k)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 65, Pay $769.91k)
  • Mr. Ajit Ramalingam, Sr. VP & Chief Accounting Officer (Age 47)
  • Diane Dahowski, Sr. VP of Global Technology & Systems
  • Mr. Timothy S. Ernst, Exec. VP, Gen. Counsel & Sec. (Age 60)
  • Colleen Corey, Sr. VP of Global HR
  • Lee Boyd, Sr. VP of Global Commercial Operations - Asia Pacific

What is (BIO.B)'s stock symbol?

(BIO.B) trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO.B."

How do I buy shares of (BIO.B)?

Shares of BIO.B can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is (BIO.B)'s stock price today?

One share of BIO.B stock can currently be purchased for approximately $605.65.

How big of a company is (BIO.B)?

(BIO.B) has a market capitalization of $18.07 billion and generates $2.31 billion in revenue each year. (BIO.B) employs 8,000 workers across the globe.

What is (BIO.B)'s official website?

The official website for (BIO.B) is www.bio-rad.com.

How can I contact (BIO.B)?

(BIO.B)'s mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, . The company can be reached via phone at 510-724-7000 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.